IFG Advisory LLC Reduces Position in Pfizer Inc. (NYSE:PFE)

IFG Advisory LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 51.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,188 shares of the biopharmaceutical company’s stock after selling 43,338 shares during the period. IFG Advisory LLC’s holdings in Pfizer were worth $1,186,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in PFE. Worth Asset Management LLC acquired a new stake in shares of Pfizer in the 1st quarter worth $29,000. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the 3rd quarter valued at approximately $30,000. GoalVest Advisory LLC grew its position in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the third quarter worth $34,000. Finally, VisionPoint Advisory Group LLC raised its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.7 %

Shares of NYSE PFE opened at $27.77 on Thursday. The business has a 50-day moving average price of $27.47 and a 200 day moving average price of $29.47. The stock has a market cap of $157.25 billion, a PE ratio of 77.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.61 and a 52-week high of $42.22.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.14 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

Analyst Ratings Changes

PFE has been the subject of a number of research analyst reports. UBS Group lowered their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Barclays decreased their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Pfizer has an average rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.